Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC
Clinical trial NCT06607926 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06607926
- Sponsor
- Xuanwu Hospital, Beijing
- Status
- NOT_YET_RECRUITING
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-15
- Primary completion
- 2025-06-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.